| アブストラクト | Risk stratification of thromboembolic events (TEs) and bleeding events is important for the appropriate selection of thromboprophylaxis in patients after the Fontan operation. Therefore, we clarified the risk factors for TEs and bleeding events in patients after the Fontan operation using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. We conducted a retrospective cohort study including 2,515 patients who underwent the Fontan operation between June 2011 and September 2019. The end points were TEs and bleeding events within 1 year of the Fontan operation analysis. We analyzed the risk factors for these end points using a multivariate analysis. In total, 1,903 patients were included in the analysis. The median age at the time of the Fontan operation was 3 (1 to 22) years, and 1,067 patients (56%) were male. The incidence rates of TEs and bleeding events were 12% and 11%, respectively. Age (odds ratio [OR] 1.1 per 1 year older, p <0.05) was an independent risk factor for TEs. Thromboprophylaxis with aspirin after the Fontan operation significantly reduced TEs (OR 0.3, p <0.05). A history of postoperative hemorrhage (OR 1.5, p <0.05) and the use of a potassium channel blocker (OR 2.1, p <0.05) were independent risk factors for bleeding events. In conclusion, aspirin was found to reduce the risk of TEs within 1 year of the Fontan operation. The results of this study will be useful in selecting effective and safe thromboprophylaxis in patients after the Fontan operation. |
|---|
| ジャーナル名 | The American journal of cardiology |
|---|
| Pubmed追加日 | 2023/10/2 |
|---|
| 投稿者 | Hosoi, Masayoshi; Ohbayashi, Masayuki; Miyahara, Yoshinori; Fujii, Takanari; Kise, Hiroaki; Kogo, Mari |
|---|
| 組織名 | Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of;Pharmacy, Showa University, Tokyo, Japan; Pfizer Japan Inc., Tokyo, Japan.;Electronic address: 23419010p@grad.showa-u.ac.jp.;Pharmacy, Showa University, Tokyo, Japan.;Pediatric Heart Disease and Adult Congenital Heart Disease Center, Showa;University Hospital, Tokyo, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37782971/ |
|---|
